Top dealmakers by $$, Q1-Q3 2012

Tools

Company: Bristol-Myers Squibb ($BMY)
Dollars: $7.8B
Targets: Amylin, Inhibitex
Focus: Diabetes drugs, hepatitis C

Company: Watson Pharmaceuticals ($WPI)
Dollars: $5.94B
Target: Actavis
Focus: Deal creates world's third largest generics company       

Company: Hologic ($HOLX)
Dollars: $3.7B
Target: Gen-Probe
Focus: Molecular diagnostics

Company: GlaxoSmithKline ($GSK)
Dollars: $3.7B
Targets: Human Genome Sciences; Cellzome
Focus: Benlysta for lupus, heart drug and HGS pipeline

Company: Dainippon Pharmaceutical
Dollars: $2.6B
Target: Boston Biomedical
Focus: BBI608 and BBI503 and a new subsidiary in the U.S. which will spearhead its expansion in the cancer drug R&D field.

   

Company: Asahi Kasei
Dollars: $2.2B
Target: Zoll Medical
Focus: Conglomerate with an interest in chemicals and fibers

Company: Agilent ($A)
Dollars: $2.2B
Target: Dako
Focus: Cancer diagnostics; antibodies, supplies, reagents, instruments

Company: Amgen ($AMGN)
Dollars: $2.17B
Targets: KAI Pharmaceuticals; Mustafa Nevzat Pharmaceuticals; Micromet
Focus: KAI-4169, which is a novel agent being studied initially for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis; Turkish pharma; oncology drug programs

Company: Novartis ($NVS)
Dollars: $1.52B
Target: Fougera Pharmaceuticals
Focus: Generic skin treatments

Company: AstraZeneca ($AZN)
Dollars: $1.26B
Target: Ardea Biosciences
Focus: Lesinurad (formerly known as RDEA594), currently in Phase III development as a potential treatment for the chronic management of hyperuricaemia in patients with gout

 

Special Report: The top M&A dealmakers in biopharma
  • (Unpublished)